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Phase II metabolism, usually known as conjugation reactions, gen-
erate metabolites that are, in most cases, biologically inactive and
subsequently excreted in bile or urine. Androgenic and estrogenic
sex steroids are mainly inactivated by sulfation or glucuronida-
tion by the enzyme families’ sulfotransferases (SULTs) or uridine
diphospho glucuronosyltransferases (UGTs). Genetic variations in
UGTs and SULTs have been implicated to play a role in hormone-
dependent diseases and in the outcome for doping test results.
Moreover, the use of drugs may interact with UGTs and SULTs
and hence affect the phase II metabolism. The aim of this research
topic forum was to highlight the progress made in this field via
review papers and original articles as well as to promote future
research with the aim to further understand the consequences of
inter-individual difference in phase II metabolism and regulation
of sex steroids.
Eight articles are included in this Research Topic, of which three
are reviews and five are original research articles. In the original
article written by Bang et al. (1), the UGT2B17 deletion polymor-
phism impact on testosterone replacement therapy was studied.
There was no association with UGT2B17 genotype and testos-
terone serum peak levels, whereas the increase in testosterone from
week 8 to 18 differed, subjects homozygous for deletion (del/del)
had a smaller increase as compared to UGT2B17 carriers. More-
over, an association between LH levels and UGT2B17 genotype
was found; del/del subjects exhibit lower levels of LH during treat-
ment period. Testosterone is not only being therapeutically used
but also a common drug together with synthetic androgens, i.e.,
nandrolone to abuse (doping). In the article by Strahm et al. (2),
it was shown that a well characterized single nucleotide polymor-
phism in UGT2B15 is associated with the glucurunidation activity
of 19-noradrosterone, the nandrolone metabolite analyzed at the
WADA accredited doping labs. The significance of different phase
II polymorphisms in female athletes was studied by Schulze et al.
(3). They confirmed that UGT2B17 deletion polymorphism is an
important determinant of T/E (a biomarker for testosterone dop-
ing) in women. Moreover, the use of hormonal contraceptives was
shown to affect the T/E ratio, which will be important to con-
sider in doping test programs. The fact that drug use can affect
the phase II metabolism and consequently doping test results were
also investigated in the original article by Lundmark et al. (4).
They found that the use of NSAIDs (diclofenac and ibuprofen)
did not interact with the urinary excretion of testosterone- and
epitestosterone-glucuronides, and hence have no impact on T/E
ratio. In the mini review by Jenkinson et al. (5), it was noted
that dietary compounds such as white and green tea inhibit testos-
terone UGT2B17-derived glucuronidation activity in vitro. Hence,
it is possible that in addition to drug use, the diet may influ-
ence the UGTs and alter the risk of hormone-related diseases and
impacting doping test results; however, this needs to be verified
in vivo.
Even though most androgens are excreted as glucuronides,
some are also subject to sulfate conjugations. We have in Schulze
et al. identified a new copy number variation polymorphism in the
SULT2A1 gene (6). This CNV alters the capacity to excrete testos-
terone and some of its metabolites in the urine. Insertions are
associated with higher excretion rate, both at basal level and after
the administration of 500 mg testosterone enanthate. It is possi-
ble that this polymorphism may alter the risk of hormone-related
diseases. In the mini review by McNamara et al., the latest findings
in phase II metabolism in relation to breast and prostate cancer
are discussed (7). Steroid sulfatase (STS), enzymes involved in the
de-conjugation of sulfated compounds, was highlighted. In addi-
tion to phase II enzymes, steroid metabolizing phase I enzymes
may determine the bioavailability of hormones. Mungenast et al.
published an extensive review about the metabolism as well as
the receptor effects of estrogens in relation to ovarian cancer,
discussing strategies to target these pathways (8).
We believe that the articles included in this Research Topic have
increased the knowledge on how genetic variation and drug use
may impact phase II metabolism in general and doping test results
in particular. Thanks to the open access policy of this journal, these
articles will reach a broad audience and we hope it will encourage
researcher to continue to conduct studies of phase II metabolism
of hormones in relation to hormone-related disease, drugs, and
doping test analysis.
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